We've found
8,265
archived clinical trials in
Rheumatoid Arthritis
We've found
8,265
archived clinical trials in
Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Updated: 12/19/2017
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Updated: 12/20/2017
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/20/2017
Click here to add this to my saved trials